DAVID FAWKS: Open Payments
NPI 1922094937 · VENICE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,789 in 115 payments from 22 companies in 2025. Trend: 2023 $1,761 · 2024 $2,311 · 2025 $2,789
Food & beverage: $2,789
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $468 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $395 |
| Alkermes, Inc. | 11 | $352 |
| ABBVIE INC. | 11 | $203 |
| Otsuka America Pharmaceutical, Inc. | 11 | $178 |
| E.R. Squibb & Sons, L.L.C. | 4 | $149 |
| Lundbeck LLC | 6 | $139 |
| Vanda Pharmaceuticals Inc. | 5 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $116 |
| Axsome Therapeutics, Inc. | 5 | $113 |
Products named: INGREZZA, CAPLYTA, REXULTI, VRAYLAR, ARISTADA, LYBALVI, COBENFY, TRINTELLIX.
Industry payments across FL — which companies pay providers there.
